EU industry responds to Lalis' letter and latest MDD (Medical Devices Directive) review text
This article was originally published in Clinica
Executive Summary
Eucomed, the European medical technology industry association, is disappointed that many of the issues that it has flagged as priorities in the context of the review of the Medical Devices Directive (MDD) have seemingly not been taken up by the Commission in the latest text of the proposed review. Although this text had still not been published as Clinica went to press, Commission director, Georgette Lalis, who oversees medical device legislation, has recently written a letter to those who responded to the public consultation on the review concerning the outcome of that consultation.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.